;PMID: 11807778
;source_file_607.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..154] = [t:42..154]
;2)section:[e:158..258] = [t:158..258]
;3)section:[e:262..360] = [t:262..360]
;4)sentence:[e:364..480] = [t:364..480]
;5)sentence:[e:481..758] = [t:481..758]
;6)sentence:[e:759..951] = [t:759..951]
;7)sentence:[e:952..1101] = [t:952..1101]
;8)sentence:[e:1102..1257] = [t:1102..1257]
;9)sentence:[e:1258..1402] = [t:1258..1402]
;10)sentence:[e:1403..1554] = [t:1403..1554]
;11)sentence:[e:1555..1763] = [t:1555..1763]
;12)sentence:[e:1764..2036] = [t:1764..2036]
;13)section:[e:2037..2069] = [t:2037..2069]
;14)section:[e:2073..2118] = [t:2073..2118]

;section 0 Span:0..37
;Int J Cancer  2002 Feb 10;97(5):562-6
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..12] Cancer) (CD:[14..18] 2002)
        (NNP:[19..22] Feb) (CD:[23..27] 10;9) (CD:[27..28] 7)
        (NN:[28..29] -LRB-) (NN:[29..30] 5) (-RRB-:[30..31] -RRB-)
        (,:[31..32] :) (CD:[32..34] 56) (::[34..37] 2-6)))

;sentence 1 Span:42..154
;K-ras mutation in helicobacter pylori-associated chronic gastritis in
;patients  with and without gastric cancer.
;[42..47]:gene-rna:"K-ras"
;[139..153]:malignancy:"gastric cancer"
(SENT
  (NP-HLN
    (NP (NN:[42..47] K-ras) (NN:[48..56] mutation))
    (PP (IN:[57..59] in)
      (NP
        (NP
          (ADJP
            (NML (NN:[60..72] helicobacter) (NNS:[73..79] pylori))
            (HYPH:[79..80] -) (VBN:[80..90] associated))
          (JJ:[91..98] chronic) (NN:[99..108] gastritis))
        (PP-LOC (IN:[109..111] in)
          (NP
            (NP (NNS:[112..120] patients))
            (PP (IN:[122..126] with) (CC:[127..130] and) (IN:[131..138] without)
              (NP (JJ:[139..146] gastric) (NN:[147..153] cancer)))))))
    (.:[153..154] .)))

;section 2 Span:158..258
;Hiyama T, Haruma K, Kitadai Y, Masuda H, Miyamoto M, Tanaka S, Yoshihara M, 
;Shimamoto F, Chayama K.
(SEC
  (FRAG (NNP:[158..164] Hiyama) (NNP:[165..166] T) (,:[166..167] ,)
        (NNP:[168..174] Haruma) (NNP:[175..177] K,) (NNP:[178..185] Kitadai)
        (NNP:[186..187] Y) (,:[187..188] ,) (NNP:[189..195] Masuda)
        (NNP:[196..198] H,) (NNP:[199..207] Miyamoto) (NNP:[208..210] M,)
        (NNP:[211..217] Tanaka) (NNP:[218..219] S) (,:[219..220] ,)
        (NNP:[221..230] Yoshihara) (NNP:[231..233] M,)
        (NNP:[235..244] Shimamoto) (NNP:[245..246] F) (,:[246..247] ,)
        (NNP:[248..255] Chayama) (NNP:[256..258] K.)))

;section 3 Span:262..360
;First Department of Internal Medicine, Hiroshima University School of
;Medicine,  Hiroshima, Japan.
(SEC
  (FRAG (NNP:[262..267] First) (NNP:[268..278] Department) (IN:[279..281] of)
        (NNP:[282..290] Internal) (NNP:[291..299] Medicine) (,:[299..300] ,)
        (NNP:[301..310] Hiroshima) (NNP:[311..321] University)
        (NNP:[322..328] School) (IN:[329..331] of) (NNP:[332..340] Medicine)
        (,:[340..341] ,) (NNP:[343..352] Hiroshima) (,:[352..353] ,)
        (NNP:[354..359] Japan) (.:[359..360] .)))

;sentence 4 Span:364..480
;Mutations of an oncogene, K-ras, are associated with the development and 
;progression of many types of human cancer.
;[390..395]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[364..373] Mutations))
      (PP (IN:[374..376] of)
        (NP
          (NP (DT:[377..379] an) (NN:[380..388] oncogene))
          (,:[388..389] ,)
          (NP (NN:[390..395] K-ras)))))
    (,:[395..396] ,)
    (VP (VBP:[397..400] are)
      (VP (VBN:[401..411] associated)
        (NP-1 (-NONE-:[411..411] *))
        (PP-CLR (IN:[412..416] with)
          (NP
            (NP (DT:[417..420] the) (NN:[421..432] development)
                (CC:[433..436] and) (NN:[438..449] progression))
            (PP (IN:[450..452] of)
              (NP
                (NP (JJ:[453..457] many) (NNS:[458..463] types))
                (PP (IN:[464..466] of)
                  (NP (JJ:[467..472] human) (NN:[473..479] cancer)))))))))
    (.:[479..480] .)))

;sentence 5 Span:481..758
;To elucidate the significance of  K-ras mutations in gastric carcinogenesis,
;we examined K-ras mutations in  gastric cancers and in Helicobacter
;pylori-associated chronic gastritis (H.  pylori-CG), which is associated with
;an increased risk for the gastric cancer  development.
;[515..520]:gene-rna:"K-ras"
;[570..575]:gene-rna:"K-ras"
;[590..605]:malignancy:"gastric cancers"
;[730..744]:malignancy:"gastric cancer"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[481..481] *))
      (VP (TO:[481..483] To)
        (VP (VB:[484..493] elucidate)
          (NP
            (NP (DT:[494..497] the) (NN:[498..510] significance))
            (PP (IN:[511..513] of)
              (NP (NN:[515..520] K-ras) (NNS:[521..530] mutations)))
            (PP (IN:[531..533] in)
              (NP (JJ:[534..541] gastric) (NN:[542..556] carcinogenesis)))))))
    (,:[556..557] ,)
    (NP-SBJ (PRP:[558..560] we))
    (VP (VBD:[561..569] examined)
      (NP (NN:[570..575] K-ras) (NNS:[576..585] mutations))
      (PP
        (PP (IN:[586..588] in)
          (NP (JJ:[590..597] gastric) (NNS:[598..605] cancers)))
        (CC:[606..609] and)
        (PP (IN:[610..612] in)
          (NP
            (NP
              (NP
                (ADJP
                  (NML (NN:[613..625] Helicobacter) (NNS:[626..632] pylori))
                  (HYPH:[632..633] -) (VBN:[633..643] associated))
                (JJ:[644..651] chronic) (NN:[652..661] gastritis))
              (NP (-LRB-:[662..663] -LRB-)
                (NML
                  (NML (NN:[663..665] H.) (NN:[667..673] pylori))
                  (HYPH:[673..674] -)
                  (NML (NN:[674..676] CG)))
                (-RRB-:[676..677] -RRB-)))
            (,:[677..678] ,)
            (SBAR
              (WHNP-1 (WDT:[679..684] which))
              (S
                (NP-SBJ-1 (-NONE-:[684..684] *T*))
                (VP (VBZ:[685..687] is)
                  (VP (VBN:[688..698] associated)
                    (NP-1 (-NONE-:[698..698] *))
                    (PP-CLR (IN:[699..703] with)
                      (NP
                        (NP (DT:[704..706] an) (VBN:[707..716] increased)
                            (NN:[717..721] risk))
                        (PP (IN:[722..725] for)
                          (NP (DT:[726..729] the)
                             (JJ:[730..737] gastric) (NN:[738..744] cancer)
                            (NN:[746..757] development)))))))))))))
    (.:[757..758] .)))

;sentence 6 Span:759..951
;Specimens of gastric cancer and H. pylori-CG were obtained from 64  gastric
;cancer patients with H. pylori-CG, 99 cancer-free H. pylori-CG patients  and
;30 H. pylori-negative healthy subjects.
;[759..786]:malignancy:"Specimens of gastric cancer"
;[827..841]:malignancy:"gastric cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[759..768] Specimens))
      (PP (IN:[769..771] of)
        (NP
          (NP (JJ:[772..779] gastric) (NN:[780..786] cancer))
          (CC:[787..790] and)
          (NP
            (NML (NN:[791..793] H.) (NN:[794..800] pylori))
            (HYPH:[800..801] -)
            (NML (NN:[801..803] CG))))))
    (VP (VBD:[804..808] were)
      (VP (VBN:[809..817] obtained)
        (NP-1 (-NONE-:[817..817] *))
        (PP (IN:[818..822] from)
          (NP
            (NP
              (NP (CD:[823..825] 64)
                (NML (JJ:[827..834] gastric) (NN:[835..841] cancer))
                (NNS:[842..850] patients))
              (PP (IN:[851..855] with)
                (NP
                  (NML (NN:[856..858] H.) (NN:[859..865] pylori))
                  (HYPH:[865..866] -)
                  (NML (NN:[866..868] CG)))))
            (,:[868..869] ,)
            (NP (CD:[870..872] 99)
              (ADJP (NN:[873..879] cancer) (HYPH:[879..880] -)
                    (JJ:[880..884] free))
              (NML
                (NML (NN:[885..887] H.) (NN:[888..894] pylori))
                (HYPH:[894..895] -)
                (NML (NN:[895..897] CG)))
              (NNS:[898..906] patients))
            (CC:[908..911] and)
            (NP (CD:[912..914] 30)
              (ADJP
                (NML (NN:[915..917] H.) (NNS:[918..924] pylori))
                (HYPH:[924..925] -) (JJ:[925..933] negative))
              (JJ:[934..941] healthy) (NNS:[942..950] subjects))))))
    (.:[950..951] .)))

;sentence 7 Span:952..1101
;K-ras mutations were examined by  polymerase chain reaction-single strand
;conformation polymorphism (PCR-SSCP),  followed by DNA sequencing analysis.
;[952..957]:gene-rna:"K-ras"
;[986..996]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-2 (NN:[952..957] K-ras) (NNS:[958..967] mutations))
    (VP (VBD:[968..972] were)
      (VP (VBN:[973..981] examined)
        (NP-2 (-NONE-:[981..981] *))
        (PP-MNR (IN:[982..984] by)
          (NP
            (NP
              (NML (NN:[986..996] polymerase) (NN:[997..1002] chain)
                   (NN:[1003..1011] reaction))
              (HYPH:[1011..1012] -)
              (NML
                (NML (JJ:[1012..1018] single) (NN:[1019..1025] strand))
                (NN:[1026..1038] conformation) (NN:[1039..1051] polymorphism)))
            (NP (-LRB-:[1052..1053] -LRB-) (NN:[1053..1061] PCR-SSCP)
                (-RRB-:[1061..1062] -RRB-))))
        (,:[1062..1063] ,)
        (S-ADV
          (NP-SBJ-1 (-NONE-:[1063..1063] *))
          (VP (VBN:[1065..1073] followed)
            (NP-1 (-NONE-:[1073..1073] *))
            (PP (IN:[1074..1076] by)
              (NP-LGS (NN:[1077..1080] DNA) (NN:[1081..1091] sequencing)
                      (NN:[1092..1100] analysis)))))))
    (.:[1100..1101] .)))

;sentence 8 Span:1102..1257
;K-ras mutations were detected in 4 of 48  (8.3%) gastric cancers, in 10 of
;163 (6.1%) H. pylori-CG and none of the 30 H.  pylori-negative healthy
;subjects.
;[1102..1107]:gene-rna:"K-ras"
;[1135..1166]:malignancy:"4 of 48  (8.3%) gastric cancers"
(SENT
  (S
    (NP-SBJ-1 (NN:[1102..1107] K-ras) (NNS:[1108..1117] mutations))
    (VP (VBD:[1118..1122] were)
      (VP (VBN:[1123..1131] detected)
        (NP-1 (-NONE-:[1131..1131] *))
        (UCP
          (PP-LOC (IN:[1132..1134] in)
            (NP
              (NP (CD:[1135..1136] 4))
              (PP (IN:[1137..1139] of)
                (NP (CD:[1140..1142] 48)
                  (PRN (-LRB-:[1144..1145] -LRB-)
                    (NP (CD:[1145..1148] 8.3) (NN:[1148..1149] %))
                    (-RRB-:[1149..1150] -RRB-))
                  (JJ:[1151..1158] gastric) (NNS:[1159..1166] cancers)))))
          (,:[1166..1167] ,)
          (PP-LOC (IN:[1168..1170] in)
            (NP
              (NP (CD:[1171..1173] 10))
              (PP (IN:[1174..1176] of)
                (NP (CD:[1177..1180] 163)
                  (PRN (-LRB-:[1181..1182] -LRB-)
                    (NP (CD:[1182..1185] 6.1) (NN:[1185..1186] %))
                    (-RRB-:[1186..1187] -RRB-))
                  (NML
                    (NML (NN:[1188..1190] H.) (NN:[1191..1197] pylori))
                    (HYPH:[1197..1198] -)
                    (NML (NN:[1198..1200] CG)))))))
          (CC:[1201..1204] and)
          (NP
            (NP (NN:[1205..1209] none))
            (PP (IN:[1210..1212] of)
              (NP (DT:[1213..1216] the) (CD:[1217..1219] 30)
                (ADJP
                  (NML (NN:[1220..1222] H.) (NNS:[1224..1230] pylori))
                  (HYPH:[1230..1231] -) (JJ:[1231..1239] negative))
                (JJ:[1240..1247] healthy) (NNS:[1248..1256] subjects)))))))
    (.:[1256..1257] .)))

;sentence 9 Span:1258..1402
;In the gastric cancer patients, mutated K-ras  was detected in differentiated
;type cancers but not in any of the  undifferentiated type cancers.
;[1265..1279]:malignancy:"gastric cancer"
;[1298..1303]:gene-rna:"K-ras"
;[1321..1348]:malignancy:"differentiated type cancers"
;[1372..1401]:malignancy:"undifferentiated type cancers"
(SENT
  (S
    (PP-LOC (IN:[1258..1260] In)
      (NP (DT:[1261..1264] the)
        (NML (JJ:[1265..1272] gastric) (NN:[1273..1279] cancer))
        (NNS:[1280..1288] patients)))
    (,:[1288..1289] ,)
    (NP-SBJ-2 (JJ:[1290..1297] mutated) (NN:[1298..1303] K-ras))
    (VP (VBD:[1305..1308] was)
      (VP
        (VP (VBN:[1309..1317] detected)
          (NP-2 (-NONE-:[1317..1317] *))
          (PP=1 (IN:[1318..1320] in)
            (NP
              (NML (JJ:[1321..1335] differentiated) (NN:[1336..1340] type))
              (NNS:[1341..1348] cancers))))
        (CC:[1349..1352] but)
        (VP (RB:[1353..1356] not)
          (PP=1 (IN:[1357..1359] in)
            (NP
              (NP (DT:[1360..1363] any))
              (PP (IN:[1364..1366] of)
                (NP (DT:[1367..1370] the)
                  
                  (NML (JJ:[1372..1388] undifferentiated) (NN:[1389..1393] type))
                  (NNS:[1394..1401] cancers))))))))
    (.:[1401..1402] .)))

;sentence 10 Span:1403..1554
;K-ras mutations in H. pylori-CG were  significantly more frequent in gastric
;cancer patients than in cancer-free  patients (10.9% vs. 3.0%, p = 0.044).
;[1403..1408]:gene-rna:"K-ras"
;[1472..1486]:malignancy:"gastric cancer"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1403..1408] K-ras) (NNS:[1409..1418] mutations))
      (PP (IN:[1419..1421] in)
        (NP
          (NML (NN:[1422..1424] H.) (NN:[1425..1431] pylori))
          (HYPH:[1431..1432] -)
          (NML (NN:[1432..1434] CG)))))
    (VP (VBD:[1435..1439] were)
      (ADVP (RB:[1441..1454] significantly))
      (ADJP-PRD
        (ADJP (RBR:[1455..1459] more) (JJ:[1460..1468] frequent))
        (PP-1 (-NONE-:[1468..1468] *ICH*)))
      (PP (IN:[1469..1471] in)
        (NP
          (NML (JJ:[1472..1479] gastric) (NN:[1480..1486] cancer))
          (NNS:[1487..1495] patients)))
      (PP-1 (IN:[1496..1500] than)
        (PP (IN:[1501..1503] in)
          (NP
            (ADJP (NN:[1504..1510] cancer) (HYPH:[1510..1511] -)
                  (JJ:[1511..1515] free))
            (NNS:[1517..1525] patients))))
      (PRN (-LRB-:[1526..1527] -LRB-)
        (FRAG
          (NP
            (NP (CD:[1527..1531] 10.9) (NN:[1531..1532] %))
            (PP (IN:[1533..1536] vs.)
              (NP (CD:[1537..1540] 3.0) (NN:[1540..1541] %))))
          (,:[1541..1542] ,)
          (S
            (NP-SBJ (NN:[1543..1544] p))
            (VP (SYM:[1545..1546] =)
              (NP (CD:[1547..1552] 0.044)))))
        (-RRB-:[1552..1553] -RRB-)))
    (.:[1553..1554] .)))

;sentence 11 Span:1555..1763
;In addition, K-ras mutations in H.  pylori-CG were significantly more
;frequent in patients with K-ras mutated  gastric cancer than in patients with
;K-ras unmutated gastric cancer (50.0% vs.  3.7%, p = 0.037).
;[1568..1573]:gene-rna:"K-ras"
;[1651..1656]:gene-rna:"K-ras"
;[1657..1680]:malignancy:"mutated  gastric cancer"
;[1703..1708]:gene-rna:"K-ras"
;[1709..1733]:malignancy:"unmutated gastric cancer"
(SENT
  (S
    (PP (IN:[1555..1557] In)
      (NP (NN:[1558..1566] addition)))
    (,:[1566..1567] ,)
    (NP-SBJ
      (NP (NN:[1568..1573] K-ras) (NNS:[1574..1583] mutations))
      (PP (IN:[1584..1586] in)
        (NP
          (NML (NN:[1587..1589] H.) (NN:[1591..1597] pylori))
          (HYPH:[1597..1598] -)
          (NML (NN:[1598..1600] CG)))))
    (VP (VBD:[1601..1605] were)
      (ADVP (RB:[1606..1619] significantly))
      (ADJP-PRD
        (ADJP (RBR:[1620..1624] more) (JJ:[1625..1633] frequent))
        (PP-1 (-NONE-:[1633..1633] *ICH*)))
      (PP (IN:[1634..1636] in)
        (NP
          (NP (NNS:[1637..1645] patients))
          (PP (IN:[1646..1650] with)
            (NP
              (NML (NN:[1651..1656] K-ras) (JJ:[1657..1664] mutated))
              (JJ:[1666..1673] gastric) (NN:[1674..1680] cancer)))))
      (PP-1 (IN:[1681..1685] than)
        (PP (IN:[1686..1688] in)
          (NP
            (NP (NNS:[1689..1697] patients))
            (PP (IN:[1698..1702] with)
              (NP
                (NML (NN:[1703..1708] K-ras) (JJ:[1709..1718] unmutated))
                (JJ:[1719..1726] gastric) (NN:[1727..1733] cancer))))))
      (PRN (-LRB-:[1734..1735] -LRB-)
        (FRAG
          (NP
            (NP (CD:[1735..1739] 50.0) (NN:[1739..1740] %))
            (PP (IN:[1741..1744] vs.)
              (NP (CD:[1746..1749] 3.7) (NN:[1749..1750] %))))
          (,:[1750..1751] ,)
          (S
            (NP-SBJ (NN:[1752..1753] p))
            (VP (SYM:[1754..1755] =)
              (NP (CD:[1756..1761] 0.037)))))
        (-RRB-:[1761..1762] -RRB-)))
    (.:[1762..1763] .)))

;sentence 12 Span:1764..2036
;These data suggest that the genetic mechanism(s) of  carcinogenesis differs
;between the differentiated type and the undifferentiated  type of gastric
;cancer and that K-ras mutations may be involved in the early  stages of
;gastric carcinogenesis of the differentiated type.
;[1852..1871]:malignancy:"differentiated type"
;[1880..1920]:malignancy:"undifferentiated  type of gastric cancer"
;[1930..1935]:gene-rna:"K-ras"
;[2016..2035]:malignancy:"differentiated type"
(SENT
  (S
    (NP-SBJ (DT:[1764..1769] These) (NNS:[1770..1774] data))
    (VP (VBP:[1775..1782] suggest)
      (SBAR
        (SBAR (IN:[1783..1787] that)
          (S
            (NP-SBJ
              (NP (DT:[1788..1791] the) (JJ:[1792..1799] genetic)
                  (NN:[1800..1812] mechanism-LRB-s-RRB-))
              (PP (IN:[1813..1815] of)
                (NP (NN:[1817..1831] carcinogenesis))))
            (VP (VBZ:[1832..1839] differs)
              (PP (IN:[1840..1847] between)
                (NP
                  (NP
                    (NP (DT:[1848..1851] the)
                       (JJ:[1852..1866] differentiated) (NN:[1867..1871] type))
                    (CC:[1872..1875] and)
                    (NP (DT:[1876..1879] the) (JJ:[1880..1896] undifferentiated)
                        (NN:[1898..1902] type)))
                  (PP (IN:[1903..1905] of)
                    (NP (JJ:[1906..1913] gastric) (NN:[1914..1920] cancer))))))))
        (CC:[1921..1924] and)
        (SBAR (IN:[1925..1929] that)
          (S
            (NP-SBJ-1 (NN:[1930..1935] K-ras) (NNS:[1936..1945] mutations))
            (VP (MD:[1946..1949] may)
              (VP (VB:[1950..1952] be)
                (VP (JJ:[1953..1961] involved)
                  (NP-1 (-NONE-:[1961..1961] *))
                  (PP-CLR (IN:[1962..1964] in)
                    (NP
                      (NP (DT:[1965..1968] the) (JJ:[1969..1974] early)
                          (NNS:[1976..1982] stages))
                      (PP (IN:[1983..1985] of)
                        (NP
                          (NP (JJ:[1986..1993] gastric)
                              (NN:[1994..2008] carcinogenesis))
                          (PP (IN:[2009..2011] of)
                            (NP (DT:[2012..2015] the)
                               (JJ:[2016..2030] differentiated)
                               (NN:[2031..2035] type))))))))))))))
    (.:[2035..2036] .)))

;section 13 Span:2037..2069
;Copyright 2001  Wiley-Liss, Inc.
(SEC
  (FRAG (NN:[2037..2046] Copyright) (CD:[2047..2051] 2001)
        (NNP:[2053..2058] Wiley) (HYPH:[2058..2059] -) (NNP:[2059..2063] Liss)
        (,:[2063..2064] ,) (NNP:[2065..2069] Inc.)))

;section 14 Span:2073..2118
;PMID: 11807778 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2073..2077] PMID) (::[2077..2078] :) (CD:[2079..2087] 11807778)
        (NN:[2088..2089] -LSB-) (NNP:[2089..2095] PubMed) (::[2096..2097] -)
        (NN:[2098..2105] indexed) (IN:[2106..2109] for)
        (NNP:[2110..2118] MEDLINE-RSB-)))
